Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and Etest methods: Report from the ARTEMIS Global Antifungal Susceptibility Program, 2001

Journal of Clinical Microbiology

Volumn 41, Issue 4, 2003, Pages 1440-1446

  Pfaller, M A ^a   Diekema, D J ^a   Messer, S A ^a   Boyken, L ^a   Hollis, R J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; VORICONAZOLE;

ANALYTIC METHOD; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH MICRODILUTION; CANDIDA; DISK DIFFUSION; ETEST; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE; PYRIMIDINES; TRIAZOLES;

BACTERIA (MICROORGANISMS); CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS;

EID: 0037387082     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.41.4.1440-1446.2003     Document Type: Article

References (38)

1. Barry, A. L., M. A. Pfaller, S. D. Brown, A. Espinel-Ingroff, M. A. Ghannoum, C. Knapp, R. P. Rennie, J. H. Rex, and M. G. Rinaldi. 2000. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J. Clin. Microbiol. 38:3457-3459.
2. Barry, A. L., M. A. Pfaller, R. P. Rennie, P. C. Fuchs, and S. D. Brown. 2002. Precision and accuracy of fluconazole susceptibility tests by broth microdilution, Etest and disk diffusion methods. Antimicrob. Agents Chemother. 46:1781-1784.
3. Berrouane, Y. F., L. A. Herwaldt, and M. A. Pfaller. 1999. Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital. J. Clin. Microbiol. 37:531-537.
4. Chryssanthou, E. 2001. Trends in antifungal susceptibility among Swedish Candida species bloodstream isolates from 1994 to 1998: comparison of the E-test and the Sensititre Yeast One colorimetric antifungal panel with the NCCLS M27-A reference method. J. Clin. Microbiol. 39:4181-4183.
5. Ellis, D., D. Marriott, R. A. Hajjeh, D. Warnock, W. Meyer, and R. Barton. 2000. Epidemiology: surveillance of fungal infections. Med. Mycol. 38(Suppl. 1):173-182.
6. Ernst, E. J. 2001. Investigational antifungal agents. Pharmacotherapy 21(Pt. 2):165S-174S.
7. Hudson, M. M. T. 2001. Antifungal resistance and over-the-counter availability in the UK: a current perspective. J. Antimicrob. Chemother. 48:345-350.
8. Hunter, P. A., and D. S. Reeves. 2002. The current status of surveillance of resistance to antimicrobial agents: report on a meeting. J. Antimicrob. Chemother. 49:17-23.
9. Jones, R. N. 1996. The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance. Diagn. Microbiol. Infect. Dis. 25:53-61.
10. Jones, R. N., and the MYSTIC Advisory Board. 2000. Detection of emerging resistance patterns within longitudinal surveillance systems: data sensitivity and microbial susceptibility. J. Antimicrob. Chemother. 46(Topic T2):1-8.
11. Kirkpatrick, W. R., T. M. Turner, A. W. Fothergill, D. I. McCarthy, S. W. Redding, M. G. Rinaldi, and T. F. Patterson. 1998. Fluconazole disk diffusion susceptibility testing of Candida species. J. Clin. Microbiol. 36:3429-3432.
12. Klepser, M. E., D. Malone, R. E. Lewis, E. J. Ernest, and M. A. Pfaller. 2002. Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob. Agents Chemother. 44:1917-1920.
13. Kronvall, G., and I. Karlsson. 2001. Fluconazole and voriconazole multidisk testing of Candida species for disk calibration and MIC estimation. J. Clin. Microbiol. 39:1422-1428.
14. Levy, S. B. 2002. Factors impacting the problem of antibiotic resistance. J. Antimicrob. Chemother. 49:25-30.
15. Lewis, D. 2002. Antimicrobial resistance surveillance: methods will depend on objectives. J. Antimicrob. Chemother. 49:3-5.
16. Masterton, R. G. 2000. Surveillance studies: how can they help the management of infection? J. Antimicrob. Chemother. 46(Topic T2):53-58.
17. Meis, J., M. Petrou, J. Bille, D. Ellis, D. Gibbs, and the Global Antifungal Surveillance Group. 2000. A global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Diagn. Microbiol. Infect. Dis. 36:215-223.
18. Morris, A. K., and R. G. Masterton. 2002. Antibiotic resistance surveillance: action for international studies. J. Antimicrob. Chemother. 49:7-10.
19. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
20. National Committee for Clinical Laboratory Standards. 2003. Method for antifungal disk diffusion susceptibility testing of yeasts: proposed guideline M44-P. National Committee for Clinical Laboratory Standards, Wayne, Pa.
21. Natsch, S., M. H. M. Steeghs, Y. A. Hekster, J. F. G. M. Meis, J. W. M. van der Mier, and B. J. Kullberg. 2001. Use of fluconazole in daily practice: still room for improvement. J. Antimicrob. Chemother. 48:303-310.
22. Pfaller, M. A. 1998. The epidemiology of invasive mycoses: narrowing the gap. Clin. Infect. Dis. 27:1148-1150.
23. Pfaller, M. A., S. A. Messer, Å. Karlsson, and A. Bolmström. 1998. Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media. J. Clin. Microbiol. 36:2586-2589.
24. Pfaller, M. A., S. A. Messer, R. J. Hollis, R. N. Jones, G. V. Doern, M. E. Brandt, and R. A. Hajjeh. 1999. Trends in species distribution and susceptibility to fluconazole among bloodstream isolates of Candida species in the United States. Diagn. Microbiol. Infect. Dis. 33:217-222.
25. Pfaller, M. A., R. N. Jones, G. V. Doern, H. S. Sader, S. A. Messer, A. Houston, S. Coffman, R. J. Hollis, and the SENTRY Participant Group. 2000. Bloodstream infections due to Candida species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998. Antimicrob. Agents Chemother. 44:747-751.
26. Pfaller, M. A., S. A. Messer, A. Houston, K. Mills, A. Bolmström, and R. N. Jones. 2000. Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different media. J. Clin. Microbiol. 38:3715-3717.
27. Pfaller, M. A., D. J. Diekema, R. N. Jones, H. S. Sader, A. C. Fluit, R. J. Hollis, S. A. Messer, and the SENTRY Participant Group. 2001. International surveillance of blood stream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program. J. Clin. Microbiol. 39:3254-3259.
28. Pfaller, M. A., and W. L. Yu. 2001. Antifungal susceptibility testing: new technology and clinical applications. Infect. Dis. Clin. N. Am. 15:1227-1261.
29. Rex, J. H., M. G. Rinaldi, and M. A. Pfaller. 1995. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39:1-8.
30. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry for the Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole and itraconazole. Clin. Infect. Dis. 24:235-247.
31. Rex, J. H., M. A. Pfaller, T. J. Walsh, V. Chaturvedi, A. Espinel-Ingroff, M. A. Ghannoum, L. L. Gosey, F. C. Odds, M. G. Rinaldi, D. J. Sheehan, and D. W. Warnock. 2001. Antifungal susceptibility testing: practical aspects and current challenges. Clin. Microbiol. Rev. 14:643-658.
32. Richet, H. M. 2001. Better antimicrobial resistance surveillance efforts are needed. ASM News 67:304-309.
33. Ruchel, R. 1997. Recurrence of Candida albicans? ISHAM Mycoses Newsl. 71:3.
34. Sandven, P., L. Bevangen, A. Digranes, P. Gaustad, H. H. Haukland, M. Steinbakk, and the Norwegian Yeast Study Group. 1998. Constant low rate of fungemia in Norway, 1991 to 1996. J. Clin. Microbiol. 36:3455-3459.
35. Sheehan, D. J., C. A. Hitchcock, and C. M. Sibley. 1999. Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 12:40-79.
36. St. Germain, G., M. Laverdiere, R. Pelletier, A.-M. Bourgault, M. Libman, C. Lemieux, and G. Noel. 2001. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J. Clin. Microbiol. 39:949-953.
37. Vazquez, J. A., G. Peng, J. D. Sobel, L. Steele-Moore, P. Schuman, W. Holloway, and J. D. Neaton for the Terry Beirr Community Programs for Clinical Research on AIDS (CPCRA). 2001. Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis. Clin. Infect. Dis. 33:1069-1075.
38. Warren, N. G., and K. C. Hazen. 1999. Candida, Cryptococcus, and other yeasts of medical importance, p. 1184-1199. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. ASM Press, Washington, D.C.